PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.50
Bid: 20.00
Ask: 21.00
Change: -2.00 (-8.89%)
Spread: 1.00 (5.00%)
Open: 22.50
High: 23.50
Low: 20.50
Prev. Close: 22.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

24 Sep 2009 07:40

RNS Number : 5870Z
Angle PLC
24 September 2009
 



For immediate release

24 September 2009

ANGLE plc ("the Company")

Director's share purchase

ANGLE plc ("ANGLE"), the international venture management company focusing on the commercialisation of technology and the development of technology-based industry, announces that it has received notification from Andrew NewlandChief Executive of ANGLE, regarding the purchase of ordinary shares of 10p each ("Ordinary Shares") in the Company.

The Company was notified on 23 September 2009 that Andrew Newland purchased in aggregate 200,000 Ordinary Shares in ANGLE at a price of 15.25 pence per share on 23 September 2009, representing 0.74% of the Company's current issued share capital. Following the purchase, Andrew Newland is beneficially interested in 7,054,686 Ordinary Shares, representing 26.00% of the Company's issued share capital.

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Collins Stewart Europe Limited

Stewart Wallace

0207 523 8350

Scott Harris 

Stephen Scott, James O'Shaughnessy, Harry Dee

0207 653 0030

Notes to Editors

ANGLE plc 

Founded in 1994, ANGLE is an international venture management company focusing on the commercialisation of technology and the development of technology-based industry. ANGLE creates, develops and advises technology businesses on its own behalf and for its clients.

ANGLE's specialist Management services business provides support on a fee-for-service basis to major clients around the world involved in incubation, IP commercialisation, SME innovation and growth and the operation of science & technology parks.

ANGLE also owns a portfolio of companies with high growth potential in the medical and technology sectors in both the UK and the US. These have been developed whilst subsidiaries of ANGLE using its proprietary Progeny® process. ANGLE seeks to retain a substantial shareholding in these companies with a view to ongoing returns from dividend, milestone, royalty and capital returns.

ANGLE's venture management and technology commercialisation skills are of increasing relevance as global economies focus on regeneration, innovation and value added components to their industries. ANGLE's technology skills in IT and software, medical and life sciences, clean tech and renewable energies are directly relevant to major growth markets of the future and are marketed as specialised Management services.

ANGLE is quoted on AIM (AGL.L); further information can be found on www.ANGLEplc.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSQZLBLKKBXBBK
Date   Source Headline
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.